Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary

J Clin Oncol. 2013 May 10;31(14):e237-9. doi: 10.1200/JCO.2012.44.3937. Epub 2013 Apr 1.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Arginine
  • Biopsy
  • Carboplatin / administration & dosage
  • Carcinoma / drug therapy
  • Carcinoma / genetics*
  • Carcinoma / pathology
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Disease-Free Survival
  • ErbB Receptors / genetics*
  • Gefitinib
  • Gemcitabine
  • Humans
  • Immunohistochemistry
  • Leucine
  • Male
  • Middle Aged
  • Molecular Targeted Therapy / methods
  • Neoplasm Staging
  • Neoplasms, Unknown Primary / drug therapy
  • Neoplasms, Unknown Primary / genetics*
  • Neoplasms, Unknown Primary / pathology
  • Point Mutation*
  • Quinazolines / therapeutic use
  • Tomography, X-Ray Computed

Substances

  • Quinazolines
  • Deoxycytidine
  • Arginine
  • Carboplatin
  • EGFR protein, human
  • ErbB Receptors
  • Leucine
  • Gefitinib
  • Gemcitabine